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Human KIT+ myeloid cells facilitate visceral
metastasis by melanoma
Chun I. Yu1,2, Jan Martinek1, Te-Chia Wu1, Kyung In Kim1, Joshy George1, Elaheh Ahmadzadeh1, Rick Maser2, Florentina Marches1,
Patrick Metang2, Pierre Authie2, Vanessa K.P. Oliveira1, Victor G. Wang1,3, Jeffrey H. Chuang1,3, Paul Robson1,3, Jacques Banchereau1,2,
and Karolina Palucka1,2,3
Metastasis of melanoma significantly worsens prognosis; thus, therapeutic interventions that prevent metastasis could
improve patient outcomes. Here, we show using humanized mice that colonization of distant visceral organs with melanoma is
dependent upon a human CD33+CD11b+CD117+ progenitor cell subset comprising <4% of the human CD45+ leukocytes.
Metastatic tumor-infiltrating CD33+ cells from patients and humanized (h)NSG-SGM3 mice showed converging transcriptional
profiles. Single-cell RNA-seq analysis identified a gene signature of a KIT/CD117–expressing CD33+ subset that correlated with
decreased overall survival in a TCGA melanoma cohort. Thus, human CD33+CD11b+CD117+ myeloid cells represent a novel
candidate biomarker as well as a therapeutic target for metastatic melanoma.
Introduction
Mechanisms sustaining the growth of human melanoma in
distant organs remain poorly defined. This is important because
metastatic dissemination remains a major clinical challenge
(Eggermont et al., 2016). Melanoma can metastasize to all organs
(Gupta and Brasfield, 1964; Einhorn et al., 1974; Meyer and
Stolbach, 1978; Nathanson et al., 1967; Patel et al., 1978), and
patients with nonpulmonary visceral metastasis, including liver,
have the worst prognosis (Balch et al., 2009). Improved survival
has been documented for patients with metastatic melanoma
treated with B-raf proto-oncogene serine/threonine kinase– and/
or mitogen-activated protein kinase kinase–targeted therapies
(Flaherty et al., 2016; Long et al., 2017) or with blocking antibodies
targeting CTL-associated protein (CTLA)-4 (Hodi et al., 2010) and/
or programmed death (PD)-1 (Wolchok et al., 2017). However, a
significant fraction of patients do not achieve prolonged survival
even in combination therapy trials and succumb to treatment-
resistant metastatic disease (Wolchok et al., 2017).
Dissemination and growth in distant organs are driven by a
complex interplay between cancer cells and their microenvi-
ronment. A number of cell types of myeloid lineage have been
implicated in cancer metastasis (Garner and de Visser, 2020). In
the mouse, neutrophils are engaged in various steps of metas-
tasis (Jaillon et al., 2020), including support of cancer cell pro-
liferation and survival (Acharyya et al., 2012; Ouzounova et al.,
2017; Szczerba et al., 2019), angiogenesis (Bekes et al., 2011;
Nozawa et al., 2006), increased extravasation of disseminated
cancer cells (Spiegel et al., 2016), and inhibition of natural killer
(NK) cell– and CTL-mediated cancer cell clearance (Coffelt et al.,
2015; Spiegel et al., 2016). Immature myeloid cells that have not
completed differentiation and are able to exert suppressive ef-
fects on adaptive immunity (i.e., myeloid-derived suppressor
cells) promote invasion, angiogenesis, and metastasis formation
(Datta et al., 2019). Furthermore, tumor-associated macrophages
promote development of metastatic disease by means of sup-
porting tumor growth in target tissues and escape from NK and
T cells (Etzerodt et al., 2019; Lewis et al., 2016; Mantovani et al.,
2017; Ruffell and Coussens, 2015). Thus, myeloid cells could
serve as putative therapeutic targets. Their remarkable hetero-
geneity makes an in-depth characterization a major goal, where
in vivo studies would bemost informative. However, differences
in myeloid cells and their downstream signaling pathways be-
tween humans and mice (Hagai et al., 2018; Kanazawa, 2007;
Mestas and Hughes, 2004; Williams et al., 2010) make it un-
certain to directly extrapolate mouse in vivo data into humans.
Here, using a transplantable model of human melanoma in hu-
manized mice, we find that CD117+CD11b+CD33+ myeloid cells
support melanoma growth in distant organs.
Results and discussion
Metastatic melanoma tumors in patients and in humanized
mice are infiltrated with CD33+ myeloid cells
To define the landscape of leukocytes in metastatic melanoma,
we analyzed transcriptional profiles of metastatic melanoma
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tumors from 14 patients with RNA sequencing (RNA-seq; Table
S1). CIBERSORT, which estimates the fraction of various leu-
kocyte RNA (Newman et al., 2015), revealed that nearly half of
the leukocyte transcripts originated frommyeloid cells (Fig. 1 A).
Modular analysis (Banchereau et al., 2016) revealed several
lymphoid modules including B cells (36 genes), T cells (107
genes), and cytotoxic/NK cells (59 genes) as well as IFN modules
(138 genes), which together clustered patient samples into two
groups (hot and cold tumors; Fig. 1 B and Table S2). Inflamma-
tion (876 genes) and myeloid (78 genes) modules were spread
across all samples (Fig. 1 B). These findings were confirmed
using The Cancer Genome Atlas (TCGA) melanoma cohort
(Cancer GenomeAtlas Network, 2015) from primary (n = 66) and
metastatic (n = 264) melanoma tumors from different patients
(Fig. S1 A). There, CIBERSORT revealed significantly higher
monocyte/macrophage–related transcripts in metastatic versus
primary tumors (Fig. 1 C). Metastatic sites also showed a sig-
nificantly higher expression of pan-myeloid marker CD33 (sialic
acid binding Ig-like lectin 3; P = 2.3e-07; Fig. 1 D). Immunoflu-
orescence staining revealed the presence of CD33+ myeloid cells
in close proximity to melanoma cells in patient tumors (Fig.
S1 B).
To study the in vivo impact of human CD33+ (hCD33+) my-
eloid cells on human melanoma, we turned to nonobese dia-
betic/severe combined immunodeficient-γ (NSG) mice with
transgenic expression of the human hematopoietic cytokines
stem cell factor (SCF), GM-CSF, and IL-3 (NSG–SCF GM-CSF IL-
3 [SGM3] mice) transplanted with hCD34+ hematopoietic pro-
genitor cells (HPCs), which support the development of hCD33+
myeloid cells (Fig. S1 C, Table S3, and Table S4; Billerbeck et al.,
2011). FACS analysis of hCD33+ cells from bone marrow, liver,
and spleen at 12 wk after hCD34+ HPC transplant using CD11b,
CD11c, CD14, CD16, CD66b, CD117, CD127, HLA-DR, and FCER1A
markers (Fig. 1, E and F; and Fig. S1, D and E) revealed the
qualitative and quantitative differences between humanized
(h)NSG and hNSG-SGM3 mice, the latter ones displaying
monocytes, granulocytes, and mast cells (Fig. S1 F). The tran-
scriptional profiles of bulk hCD33+ cells from the spleen and
liver of hNSG and hNSG-SGM3 mice at 12 wk after hCD34+ HPC
transplant confirmed the phenotypic divergence between the
two strains (Fig. 1 G and Table S5), with granulocyte adhesion
and diapedesis and Th2 cell pathways significantly enriched in
hCD33+ cells from hNSG-SGM3 mice (Fig. 1 H).
hNSG-SGM3 mice support distant organ colonization
with melanoma
We then implanted the two humanized mouse strains with 107
Me275 human melanoma cells s.c. (Fig. 2 A; Rongvaux et al.,
2014). Upon necropsy before any tumor-induced mortality,
hNSG-SGM3 mice displayed a vastly greater number of macro-
scopic tumors in the spleen and liver than hNSG mice (Fig. 2 B;
and Fig. S2, A–C), while implantation site s.c. tumors (primary
tumors) grew at similar rates in both strains (Fig. 2 C). Immu-
nofluorescence staining for melanoma-associated proteins,
melanoma antigen recognized by T cells 1 (MART-1), and gly-
coprotein 100 (gp100) confirmed the presence of melanoma cells
and tumor formation in distant visceral organs (Fig. 2 D and Fig.
S2 D). Tumors were imaged in vivo or ex vivo with an in vivo
imaging system (IVIS) to detect luciferase-labeled Me275 cells
(Fig. 2, E and F). Luciferase signal was present in multiple vis-
ceral organs (liver, spleen, pancreas, stomach, kidney, lungs, and
bone; Fig. 2 E). Kinetic experiments following the appearance of
macroscopic tumors as well as luminescence signal reflecting
tumor growth in vivo revealed that Me275 cells require at least
42 d for visceral tumors to appear (Fig. 2, F and G).
To determine if human leukocytes were involved, we com-
pared Me275 tumor growth in NSG-SGM3 mice with or without
a human immune system. Only sporadic macroscopic tumors in
visceral organs could be found upon necropsy (Fig. 2 H), and no
MART-1/gp-100 staining could be detected in the liver harvested
from nonhumanized mice (Fig. 2 I). In contrast, distant organs
were colonized with Me275 cells in hNSG-SGM3 mice (Fig. 2, H
and I). In both cases, Me275 cells grew at the primary site at
similar kinetics (Fig. S2 E). Thus, human leukocytes are critical
for distant organ colonization by melanoma cells. This was
further confirmed by adoptive cell transfer (ACT) experiments
where hCD45+ leukocytes were purified from the liver and
spleen of tumor-naive hNSG-SGM3 mice and adoptively trans-
ferred (107 cells) into nonirradiated tumor-naive nonhumanized
NSG-SGM3 mice or NSG mice. Both cohorts were implanted
with Me275 cells s.c. immediately thereafter (Fig. 2 J). NSG-
SGM3 mice adoptively transferred with hCD45+ leukocytes
showed significantly higher numbers of melanoma tumors in
the liver than controls without ACT (Fig. 2 K). In contrast, NSG
mice adoptively transferred with hCD45+ cells purified from
hNSG-SGM3mice developed only sporadic liver tumors (Fig. 2 K).
Thus, the capacity of hCD45+ leukocytes to support melanoma
growth in distant organs is dependent on at least one of the host
human cytokines SCF, GM-CSF, and/or IL-3.
Distant organ colonization is dependent upon hCD33+
myeloid cells
Tissue examination revealed close proximity of hCD33+ cells and
melanoma cells in the liver and spleen of hNSG-SGM3 mice
(Fig. 3 A). The transcriptional profiles of hCD33+ cells purified
from the spleen and liver of hNSG-SGM3 mice were established
using RNA-seq, and the analysis was focused on the myeloid
gene set selected by Nanostring. The Venn diagram analysis
revealed a 78% overlap in myeloid gene expression between
melanoma metastases from patients and hCD33+ cells from mice
(Fig. 3 B). The top networks were driven by the expression of
STAT3, STAT1, and NFKB1, identical to those observed in mela-
noma patients (Fig. 3 C, Fig. S2 F, Table S6, and Table S7). To
establish whether hCD33+ myeloid cells are involved in tumor
formation, hCD45+ cells isolated from the liver and spleen of
hNSG-SGM3 mice were subdivided using magnetic beads into
hCD33+ and hCD33neg cell fractions (Fig. 3 D) and used in ACT
experiments as described above. Recipient mice that received
hCD33+ cells showed melanoma tumors in the spleen and in the
liver, while those that received hCD33neg cells did not (Fig. 3 E;
with no impact on the growth of the primary tumors as shown in
Fig. S2 G).
hCD11b+ cells represent a large fraction of hCD33+ cells (71% ±
14%; range, 57–87%; n = 4; Fig. 4 A), and the ACT of CD11b-depleted
Yu et al. Journal of Experimental Medicine 2 of 11
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Figure 1. Human myeloid cells in metastatic melanoma tumors and hNSG-SGM3 mice. (A) CIBERSORT analysis of RNA-seq data from 14 metastatic
patient melanoma tumors (two samples from different areas of one patient tumor). (B) GSVA score of patient tumors using defined modules as gene sets.
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CD45+ cells resulted in a lower number of liver tumors in a frac-
tion of mice (0.7 ± 0.6 in the hCD11bneg group; Fig. 4 B) while
hCD11b+ cells could enhance liver tumors (12.8 ± 12.4, n = 4 mice;
Fig. S2 H), suggesting that these cells play a role. hCD11b+ cells
include CD66b+ cells that contain mature granulocytes and are
present in hNSG-SGM3 but not in hNSG mice (Fig. S1 F), CD14+
cells of monocytic lineage, and cells with an intermediate ex-
pression of CD117 (Fig. 4 A). We did not observe any significant
difference in liver tumors of mice transferred with CD66b-
depleted cells or CD66b-enriched cells (Fig. S2, I and J), suggest-
ing that CD66b+ cells are not essential for colonization of liver in
hNSG-SGM3 mice. Similarly, depletion of CD14+ cells did not im-
pact distant tumor development (Fig. S2, K and L), indicating that
cells of monocytic lineage are dispensable. Thus, hCD33+ cells
contain cell subset(s), distinct from mature granulocytes and
monocytes, able to support melanoma growth in the liver.
Distant organ colonization is mediated by
hCD33+CD11b+CD117+ cells
hCD117+ (KIT+) cells were enriched in hNSG-SGM3mice compared
with hNSG (Fig. S1 F). The expression of CD117 within hCD33+ cells
was heterogeneous, with at least three cell populations detectable
by surfacemarker expression: CD33+CD11b+CD117neg, CD33+CD11b+
CD117+, and CD33+CD11bnegCD117+ (Fig. 4 A). Because NSG mice
expressing membrane-bound human SCF (NSG-mSCF) develop
CD117+ tryptase+ mature humanmast cells (Takagi et al., 2012), we
constructed hNSG-mSCF mice and implanted them s.c. with 106
Me275 cells. We did not detect tumors in the liver, and only
sporadic spleen tumors in two of eight mice (Fig. 4 C), while there
was a comparable primary tumor growth (Fig. S2 M). Further-
more, NSG-SGM3micewith ACT of FCER1A-depleted hCD45+ cells
displayed disseminated tumors in the liver (Fig. S2, N and O).
Thus, hFCER1A+ (a marker of mature mast cells and basophils)
cells are dispensable. However, depletion of hCD117+ cells resulted
in a significant decrease in the number of mice with liver tumors
as well as in the number of liver tumors per mouse in two inde-
pendent experiments (1–35 in hCD45+ transferred mice, n = 11/13
vs. 0–6 in CD117-depleted hCD45+ transferredmice, n = 2/12; Fig. 4,
D and E; and Fig. S2 P). Conversely, ACT of hCD117+ cells enriched
from liver/spleen into nonhumanized NSG-SGM3 mice sup-
ported the development of liver tumors (range, 4–90) in the liver
in five of five mice (Fig. 4 E and Fig. S2 P). Thus, the ca-
pacity to promote melanoma growth in distant organs lies
within hCD33+CD11b+CD117+ precursor/progenitor cells, which
represent ∼4% of the hCD45+ cells in hNSG-SGM3 mice.
Single-cell RNA-seq (scRNA-seq) of hCD33+ cells from the
liver/spleen of hNSG-SGM3 mice (Fig. 4 F; Fig. S3, A–C; and
Table S8) revealed that KIT+ cells, which coexpress ITGAM
(CD11b) and IL3RA but not CSF2RA (Fig. 4 G), are composed of
four clusters (Fig. 4 F, clusters 2, 3, 5, and 7; and Fig. S3, B and C),
including two clusters of cells expressing transcripts coding for
mast cell proteolytic enzymes (TPSAB1, TPSB2) and leukotriene
catabolism (HPGD, HPGDS, LTC4S; clusters 2 and 3); one cluster
of mature mast cells with high expression of high-affinity IgE
receptor (FCER1A) and CCR3 (cluster 7); and one cluster of di-
viding progenitor cells expressing cell cycle and DNA synthesis
genes (cluster 5). In line with this, tissue analysis revealed dif-
ferences between CD117 and tryptase expression in both ex-
perimental metastatic tumors in hNSG-SGM3 mice and in
metastasis from melanoma patients (Fig. S3, D–F). As the de-
pletion of FCER1A-expressing cells did not impact melanoma
growth in distant organs (Fig. S3 I), we conclude that pro-
metastatic activity is distant from mature mast cells and is
linked with progenitor cells.
We then stratified the cells into two groups based on the
expression level of the KIT gene (Fig. 4 H) to establish the
transcriptome of KIT+ cells. The differentially expressed genes
(DEGs) between the two groups of cells were computed using the
Wilcoxon rank sum test. All the genes that had an absolute
log2 fold-change value >0.2 and a false discovery rate of <5%
were selected as KIT signature genes (n = 221; Table S9). The
prognostic significance was evaluated using the log2 fold-
change weighted mean expression of the KIT signature
genes in samples in TCGA (Cancer Genome Atlas Network,
2015). Since the score is a measure of the specific cell type,
the samples were then stratified into two groups based on the
median of the score, and the survival difference in the two
groups was visualized using Kaplan-Meier plots (Fig. 4 I). The
Kaplan-Meier analysis revealed that the high KIT score was
associated with significantly lower survival probability (P <
0.0005; hazard ratio = 1.94; 95% confidence interval =
1.33, 2.82).
Thus, hCD33+CD11b+CD117+ myeloid cells facilitate distant
organ colonization by human melanoma after subcutaneous
implantation. The molecular mechanisms regulating the ability
of these cells to promote tumor growth in our model remain to
be identified. Importantly, despite the presence of endogenous
murine myeloid cells, the distant organ colonization is sporadic
in the absence of human myeloid cells. This suggests that the
molecular pathways governing myeloid cell–dependent mela-
noma growth are restricted in the absence of human cells. Our
studies herein suggest a potential novel prognostic biomarker
and downstream effector molecule(s) that might represent a
therapeutic target.
(C) CIBERSORT analysis of RNA-seq data from TCGA primary (n = 66) and metastatic (Met) melanoma (n = 264) tumors. Values are mean percentage. Two-way
ANOVA with Bonferroni’s multiple comparisons test. ****, P < 0.0001; **, P < 0.01. (D) CD33 expression in TCGA primary and metastatic melanoma tumors.
P = 2.3 × 10−7 Wilcoxon test. The error bar is the SD. (E) hCD33+ cells from the spleen of three hNSG (blue) and three hNSG-SGM3 (orange) mice were gated
and subjected to t-distributed stochastic neighbor embedding (tSNE) reduction. Indicated markers were color-mapped from blue (low density) to red (high
density) into the tSNE map. (F) tSNE plots of hCD33+ cells from the liver as analyzed in E. (G) Bulk RNA-seq of hCD33+ cells enriched and pooled from the
spleen and liver of hNSG and hNSG-SGM3 mice. DEGs were illustrated in the dot plot using log2 fold change as the x axis and TPM of hNSG (blue) or hNSG-
SGM3 (orange) as the y axis with criteria of logTPM expression ≥1 and absolute log2 fold change ≥1 (dotted lines). (H) Heatmap comparing IPA on the DEGs in
CD33+ cells from hNSG and hNSG-SGM3 mice for immune canonical pathway analysis. Eos, eosinophils; DCs, dendritic cells; MCs, mast cells; gd T, γΔ T cells;
Mono/Mac, monocyte/macrophage; PC, plasma cells; PMN, polymorphonuclear leukocytes. fMLPN, formyl-L-methionyl-L-leucyl-phenylalanine.
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Figure 2. hNSG-SGM3mice promote melanoma growth in distant organs. (A)Mice were engrafted with hCD34+ HPCs at 4 wk, implanted with 107 Me275
cells s.c. at 14–16 wk, and analyzed at 22–24 wk of age (7–8 wk after tumor implantation) before succumbing to the disease. (B) Number of macroscopic
tumors in the spleen and liver of hNSG and hNSG-SGM3 mice. Two-tailed Mann-Whitney test. Data are combined from a total of 14 hNSG and 15 hNSG-SGM3
mice from three independent experiments (i.e., separate mouse cohorts) using two CD34+ HPC donors. Mets, metastases. (C) Me275 tumor growth in hNSG
and hNSG-SGM3 mice as in B. (D) Localization of MART-1/gp100 (green) and DAPI (blue) in the liver of hNSG-SGM3 mice at 8 wk. Scale bar = 1 mm for the
whole section and 20 µm for the selected zoom-ins. (E)Mice bearing luciferase-labeled Me275 tumors were harvested, and individual organs were analyzed by
IVIS. Representative images of a control mouse and three hNSG-SGM3 mice at 8 wk after 106 Me275 s.c. implantation. Tumor, s.c. implantation site. aLN,
auxiliary LN; mesLN, mesenteric LN; nd, not done. (F) hNSG and hNSG-SGM3 mice were implanted with 106 luciferase-labeled Me275 cells; tumor growth was
monitored weekly by IVIS (n = 2mice per group). (G)Mice bearing luciferase-labeledMe275 tumor were harvested at different time points, and individual organ
was analyzed by IVIS. (H) Number of macroscopic tumors in the spleen and liver of NSG-SGM3 and hNSG-SGM3 mice implanted with 107 Me275 cells s.c.
Yu et al. Journal of Experimental Medicine 5 of 11
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Materials and methods
Cell lines
Melanoma cancer cell line Me275 (Research Resource Identifier
[RRID]:CVCL_S597), which was established from surgically
excised melanoma metastases from patient LAU50, was pro-
vided by Pedro Romero at the Ludwig Institute for Cancer Re-
search at the University of Lausanne (Lausanne, Switzerland).
Tumor cells were cultured in complete RPMI (RPMI 1640,
n = 12–13 mice per strain, two-tailed Mann-Whitney test. (I) Localization of hCD45 (red), MART-1/gp100 (green), and DAPI (blue) in the liver from one mouse
per strain from H. Scale bar = 1 mm for the whole section and 60 µm for the selected zoom-ins. (J) Outline of the experiment. 107 hCD45+ cells enriched from
naive hNSG-SGM3 mice were transferred i.v. into NSG-SGM3 or NSG mice and subsequently implanted with 107 Me275 cells s.c. on the same day. (K)
Macroscopic tumors in the liver at 8 wk after ACT as in J. n = 5 mice per recipient group, one-way ANOVA test. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01. p,
photons; sr, steradiance.
Figure 3. Melanoma colonization in hNSG-SGM3 mice is dependent on hCD33+ cells. (A) Immunofluorescence staining of MART-1/gp100 (green), CD33
(red), and DAPI (blue) in the liver and spleen of hNSG-SGM3 mice at 8 wk after 107 Me275 s.c. implantation. Scale bar = 1 mm for the whole section and 100 µm
for the selected zoom-ins. (B) Venn diagram illustrating human myeloid genes expressed in patient melanoma tumors and CD33+ cells in hNSG-SGM3 mice.
(C) IPA on myeloid genes in CD33+ cells from hNSG-SGM3 mice for the upstream regulator. Top five regulators, STAT3, RELA, STAT1, NFKB1, and SPI1, are
illustrated with the top 20 genes of each network. (D) Expression of hCD33 in enriched cells by FACS. (E)Macroscopic tumors in the spleen and liver of NSG-
SGM3 mice after i.v. ACT of 107 hCD33+ or hCD33neg cells and subsequently implanted s.c. with 107 Me275 cells. n = 7–9 mice per recipient group, one-way
ANOVA test. FSC, forward scatter; Mets, metastases. **, P < 0.01.
Yu et al. Journal of Experimental Medicine 6 of 11
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Figure 4. hCD33+CD11b+CD117+ myeloid cells promote visceral organ colonization. (A) Expression of hCD11b versus CD33, CD66b, CD14, and CD117 on
enriched hCD45+ or CD11b+ cells from naive hNSG-SGM3 mice for ACT. (B) Macroscopic Me275 tumors in the livers of NSG-SGM3 mice after i.v. ACT of 107
hCD45+ or hCD11bneg cells and subsequent s.c. implantation of 107 Me275 cells. n = 3–5 mice per recipient group, t test. (C) hNSG, hNSG-SGM3, and hNSG-
mSCF (labeled hmSCF) mice were implanted s.c. with 106 Me275 cells. Number of macroscopic tumors in the livers of mice from two independent experiments
using two HPC donors. n = 6–8 mice per strain, one-way ANOVA test. (D) Expression of hCD33 and CD117 on cells enriched for CD117+ from naive hNSG-SGM3
mice for ACT. (E)Macroscopic Me275 tumors in the livers of NSG-SGM3 mice after ACT of 107 hCD117+ or hCD117neg cells i.v. and subsequent s.c. implantation
of 107 Me275 cells. n = 3–8 mice per recipient group, one-way ANOVA test. (F) scRNA-seq analysis of hCD33+ cells enriched from the spleen and liver of hNSG-
SGM3 mice. 13 clusters with distinct transcriptional profiles are visualized using tSNE plot. ILC, innate lymphoid cells; DCs, dendritic cells. (G) KIT-, IL3R-,
CSF2RA-, and ITGAM-expressing cells were color-mapped using tSNE plots. (H) DEGs on KIT+ cells (log expression ≥1) and KITneg cells (log expression = 0) from
Yu et al. Journal of Experimental Medicine 7 of 11
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25 mM Hepes, 1 mM sodium pyruvate, 1% nonessential amino
acid, 1% penicillin-streptomycin, and 2 mM L-glutamine) sup-
plemented with 10% FBS at 37°C with 5% CO2 atmosphere and
authenticated using Short Tandem Repeat profiling analysis by
the American Type Culture Collection. The mycoplasma test
was performed regularly, and cells were negative for myco-
plasma before each experiment.
Lentiviral transduction
The Me275 tumor cell lines were transduced with lentiviral
vector (pLX302-CMV-Luc2) at varying multiplicity of infection
by incubating virions in the culture medium containing 8 µg/ml
polybrene (Sigma). Stably transduced cells were selected with
3 µg/ml puromycin (InvivoGen). Stable cell lines expressing
luciferase protein were confirmed by anti-luciferase (Luci21
1–107; Novus) intracellular staining.
Humanized mice
Humanized mice were generated on NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ; RRID:IMSR JAX:005557), NSG-SGM3 (NOD.Cg-
Prkdcscid Il2rgtm1WjlTg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ;
RRID:IMSR JAX:013062), and NSG-mSCF (NOD.Cg-Prkdcscid
Il2rgtm1Wjl Tg(PGK1-KITLG*220)441Daw/SzJ; RRID:IMSR JAX:
017830) obtained from The Jackson Laboratory. All protocols
were reviewed and approved by the Institutional Animal Care
and Use Committee at The Jackson Laboratory (14005) and
University of Connecticut Health Center (101163–0220). De-
identified human specimens were obtained from vendors and
approved by The Jackson Laboratory Institutional Review
Board. Mice were sublethally irradiated (10 cGy per gram of
body weight) using γ irradiation at the age of 4 wk. 100,000
CD34+ HPCs from fetal liver or full-term cord blood (Advanced
Bioscience Resources or Lonza) were given by tail-vein i.v.
injection in 200 µl PBS. Mice were bled at 8–12 wk after HPC
transplant to evaluate engraftment and were euthanized ac-
cording to the individual experimental design.
Flow cytometry analysis
For human engraftment, heparinized blood samples were first
treated with RBC lysis buffer (Biolegend), followed by the
treatment of both human and murine Fc Block (BD Biosciences)
and then stained on ice with antibodies tomouse CD45 (30-F11; BD
Biosciences) and hCD45 (HI30; BD Biosciences), CD14 (MqP9; BD
Biosciences) or CD33 (P67.6; Biolegend), CD19 (HIB19; Biolegend),
and CD3 (SK7; BD Biosciences) for 30 min (Table S10). Antibodies
to mouse and hCD45 were species-specific antibodies to pan-
leukocytes including myeloid cells. After washing twice with
PBS, the samples were acquired on an LSRII or Symphony A5 (BD
Biosciences) and analyzed with FlowJo software (Tree Star). For
immunophenotype, bonemarrow (femur and tibia), spleen, livers,
lungs, and blood were collected. Tissues were first digested with
25 µg/ml Liberase (Roche Diagnostics) and DNase I (Sigma) at
37°C, 10min for the spleen and 30min for livers and lungs. Single-
cell suspensions were made, and the debris was removed by
filtering through a 70-µm cell strainer. Cells were first
treated with RBC lysis buffer, followed by the treatment of
both human and murine Fc Block, and then stained on ice
with fluorescence-conjugated antibodies to mouse CD45 (30-
F11; BD Biosciences) and hCD45 (HI30; BD Biosciences), CD3
(OKT3; BD Biosciences), CD19 (HIB19; Biolegend) or CD20
(2H7; Biolegend), CD33 (P67.6; Biolegend), CD11b (ICRF44;
Biolegend), CD11c (B-ly6; BD Biosciences), CD14 (MqP9; BD
Biosciences), CD16 (3G8; BD Biosciences), CD66b (G10F5;
Biolegend), CD117 (104D2; Biolegend), CD127 (HIL-7R-M21;
BD Biosciences), FCER1A (AER-37; Biolegend), and HLA-DR
(G46-6; BD Biosciences) for 30 min (Table S10). After
washing twice with PBS, the samples were stained with
7-aminoactinomycin D (Biolegend) and acquired on LSRII or
Symphony A5 (BD Biosciences) and analyzed with FlowJo
software (Tree Star).
Tumor model
Tumor cells were injected s.c. into the flank of the mice. Tumor
size was monitored every 7 d with a caliper. Tumor volume
(ellipsoid) was calculated as follows: (short diameter)2 × long
diameter/2. Alternatively, luciferase-labeled melanoma cells were
injected i.v. into the mice. Mice were killed, and the macroscopic
metastases were identified and scored in various organs including
lymph nodes (axillary and brachial), livers, spleen, kidneys, and
lungs.
Human immune cell purification and ACT
At 12–16 wk after transplant, hNSG-SGM3 mice were eutha-
nized, and spleen and liver were collected for single-cell sus-
pension. Spleen and liver were first digested with 25 µg/ml
Liberase (Roche Diagnostics) for 10–30 min at 37°C; single-cell
suspensions weremade, and the debris was removed by filtering
through a 70-µm cell strainer. Live cells were isolated using
Ficoll-Paque Plus density gradient centrifugation. Human im-
mune cells were enriched by using the Mouse/Human Chimera
isolation kit (StemCell Technologies) following the manu-
facturer’s protocol. For the enrichment of CD33+ or CD33neg cells,
enriched hCD45+ cells were further stained with PE-conjugated
CD33 antibody (WM53; Biolegend) for 15 min and enriched by
using EasySep PE selection kit (StemCell Technologies). For
CD14, CD11b, CD66b, CD117, and FCER1A depletion, hCD45+ cells
were further stained with PE-conjugated CD14 (MϕP-9; BD
Biosciences), CD11b (IRCF44; Biolegend), CD66b (G10F5; Biolegend),
CD117 (104D2; Biolegend), and FCER1A (AER-37; Biolegend)
antibodies (Table S10) for 15 min and enriched by using the
EasySep PE selection kit (StemCell Technologies). Isolated
human immune cells had purity exceeding 95%. Human im-
mune cells were adoptively transferred at 107 cells per mouse
by tail-vein i.v. injection.
scRNA-seq of hCD33+ cells were analyzed using a mixture-modeling approach and rank ordered based on the log fold change. The top 30 up-regulated and
down-regulated DEGs in KIT+ cells are illustrated using the hierarchically clustered heatmap. (I) Kaplan-Meier analysis comparing survival of melanoma patients
from TCGA stratified by median KIT score. P = 0.00045 with the log-rank test. Mets, metastases. ****, P < 0.0001; ***, P < 0.001; *, P < 0.05.
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In vivo imaging
Before mice were anesthetized with Isoflurane, an aqueous so-
lution of luciferin (150 mg/kg i.p.) was injected 10 min before
imaging with IVIS (PerkinElmer). The animals were placed into
the light-tight chamber of the charge-coupled device camera
system, and the photons emitted from the luciferase-expressing
cells within the animal were quantified using Living Image
(PerkinElmer). To image dissected organs, mice were first in-
jected i.p. with luciferin (150 mg/kg) for 10 min and quickly
killed to remove each organ. Organs were imaged in 12-well
culture dishes with PBS containing 300 µg/ml luciferin.
Immunofluorescence staining
Tissues were embedded in optimal cutting temperature media
(Sakura Finetek U.S.A.) and snap-frozen in liquid nitrogen.
Frozen sections were cut at 6 µm, air-dried on Superfrost plus
slides, and fixed with cold acetone for 5 min. Tissue sections
were first blocked with Background Buster, followed by treat-
ment of Fc Receptor Block (Innovex Bioscience). The sections
were then stained with mouse monoclonal antibodies to human
MART-1 (M2-2C10 andM2-9E3; Novus Biologicals), gp100 (NK1-
beteb; LifeSpan BioSciences), CD45 (HI30; Biolegend), CD33
(P67.6; Biolegend), CD11b (ICRF44), CD117 (104D2; Biolegend),
and tryptase (AA1; Biolegend) for 1 h at room temperature (Table
S10). Respective isotype antibodies were used as the control.
Finally, sections were counterstained with 1 µg/ml of DAPI,
mounted with Fluoromount (Thermo Fisher Scientific), ac-
quired using a Leica SP 8 confocal microscope with Leica LAS X
software, and analyzed using Imaris software (Bitplane).
RNA-seq
Total RNA was isolated from snap-frozen metastatic melanoma
tissues (Table S1; Cooperative Human Tissue Network, Penn-
sylvania) and CD33+ cells from the spleen and livers of hNSG-
SGM3 and hNSG mice using the RNA isolation kit following the
manufacturer’s protocol (Qiagen). Total RNA isolated was run
on a Qubit (Thermo Fisher Scientific) and a Bioanalyzer 2100
Nano Chip (Agilent Technologies) to check RNA quantity and
quality. Sequencing libraries were prepared using KAPA
Stranded mRNA-seq kit (Roche) according to the manufacturer’s
protocol. First, poly-A RNA was isolated from 300 ng total RNA
using oligo-dT magnetic beads. Purified RNA was then frag-
mented at 85°C for 6 min, targeting fragment range 250–300 bp.
Fragmented RNA was reverse transcribed with an incubation of
25°C for 10 min and 42°C for 15 min and an inactivation step at
70°C for 15 min. This was followed by second strand synthesis at
16°C for 60min. Double-stranded cDNA fragments were purified
using Ampure XP beads (Beckman Coulter), then A-tailed and
ligated with Illumina adapters. Adapter-ligated DNA was puri-
fied using AMPure XP beads and followed by 10 cycles of PCR
amplification. The final library was cleaned up using AMPure XP
beads. Quantification of libraries was performed using real-time
quantitative PCR (Thermo Fisher Scientific). Sequencing was
performed on an Illumina NextSeq 500 platform generating
single-end reads of 75 bp. All primary analysis of RNA-seq was
processed using CASAVA pipeline (Illumina, v1.8.2). Sequences
were aligned with Bowtie 2 (Kim et al., 2013), and counts were
generated with RSEM (Anders et al., 2015) using the annotations
from Ensembl GRCh37 (Harrow et al., 2012). The files from
alignment result were converted to BAM format using SAMtools
(Li et al., 2009). Raw counts were normalized to log2 trans-
formed transcript per million (TPM) or fragments per kilobase of
transcript per million mapped reads (FPKM; log2(FPKM + 1)).
CIBERSORT was used to estimate the proportions of diverse
immune cell types using the genes that define the signature
expression of the immune cell types. We used the default 22 cell
types (LM22) provided (Newman et al., 2015). For modular
analysis, a set of 260 transcriptional modules was used as a
preexisting framework (Banchereau et al., 2016). Module-level
activity score was calculated by R package gene set variation
analysis (GSVA) score from RNA-seq data (Hänzelmann et al.,
2013). Ingenuity pathway analysis (IPA; Qiagen) was applied to
reveal transcriptional networks, and ClueGO was used to illus-
trate biological interpretation of genes (Bindea et al., 2009).
scRNA-seq
Enriched hCD33+ cells from liver and spleen of hNSG-SGM3
mice were resuspended in PBS containing 0.04% BSA, the cell
numbers were counted on the Contess II automated cell counter
(Thermo Fisher Scientific), and ∼12,000 cells were loaded per
channel on Chromium microfluidic chips (10x Genomics). Single-
cell capture, barcoding, and library preparation were performed
using the 10x Chromium version 2 chemistry according to the
manufacturer’s protocol (10x Genomics). The quality of cDNA and
libraries was checked on an Agilent 4200 TapeStation, quantified
by KAPA quantitative PCR, and sequenced on a HiSeq 4000 (Il-
lumina) to an average depth of 50,000 reads per cell. We quan-
tified gene expression counts from raw sequencing data using Cell
Ranger v2.2 with GRCh38. Datasets from liver and spleen of two
independent experiments were normalized using Harmony
(Korsunsky et al., 2019).
Database and statistical analysis
Statistical analysis was performed in Prism 8 (GraphPad). Figure
legends denote P values as follows: ****, P < 0.0001; ***, P < 0.001;
**, P < 0.01; and *, P < 0.05. Comparisons between any two groups
were analyzed using the Mann-Whitney test or two-tailed t test,
and comparisons between any three or more groups were analyzed
byANOVAas indicated in the respective legends. TheKaplan-Meier
curves of melanoma patient data were generated using RNA-seq
data from the TCGA–skin cutaneous melanoma project (Cancer
Genome Atlas Network, 2015). The DEGs between the two groups
of cells were computed using the Wilcoxon rank sum test. The
statistical significance of the difference in the Kaplan-Meier sur-
vival plot was computed using the log-rank test using R package.
Data availability
RNA-seq data have been deposited at the NCBI Sequence Read
Archive with accession no. SRP141256 (https://www.ncbi.nlm.
nih.gov/Traces/study1/?acc=SRP141256&go=go), and scRNA-seq
data have been deposited in the NCBI Gene Expression Omni-
bus with accession no. GSE161957 and Sequence Read Archive
with accession no. SRP293689 (https://www.ncbi.nlm.nih.gov/
Traces/study1/?acc=SRP293689&go=go).
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Online supplemental material
Fig. S1 shows human myeloid cells in metastatic melanoma tu-
mors and hNSG-SGM3 mice. Fig. S2 shows that hNSG-SGM3
mice promote melanoma growth in distant organs via hCD33+
cells. Fig. S3 shows the expression of hCD117 in hNSG-SGM3
mice and metastatic melanoma tumor. Table S1 shows the list
of melanoma patient tumors used in the study. Table S2 shows
the list of genes in annotated immune modules. Table S3 shows
the kinetics of human engraftment in the blood of hNSG and
hNSG-SGM3 mice. Table S4 shows human engraftment in the
tissues of hNSG and hNSG-SGM3 mice. Table S5 shows DEGs of
bulk RNA-seq on hCD33+ cells enriched from the spleen and
liver of hNSG and hNSG-SGM3 mice. Table S6 shows IPA on
upstream regulator for the myeloid genes expressed in CD33+
cells from hNSG-SGM3 mice. Table S7 shows IPA on upstream
regulator for the myeloid genes expressed in human melanoma
tumors. Table S8 showsmarker genes specific for each cluster in
scRNA-seq of hCD33+ cells from hNSG-SGM3 mice. Table S9
shows KIT signature genes identified from scRNA-seq of hCD33+
cells from hNSG-SGM3 mice. Table S10 shows the list of anti-
bodies used in the study.
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Figure S1. Humanmyeloid cells inmetastatic melanoma tumors and hNSG-SGM3mice. (A)Heatmap representing the GSVA enrichment score of primary
or metastatic patient melanoma tumors (skin/soft tissues, lymphoid nodes, or distant organs) using defined modules as gene sets. (B) H&E and immuno-
fluorescence staining of MART-1/gp100 (green), CD33 (red), and DAPI (blue) on metastatic human melanoma tumor from the liver. Scale bar = 2.5 mm and
20 µm for the zoom-in. (C) FACS plots illustrate the percentage of hCD33+ cells in hNSG and hNSG-SGM3 (labeled hSGM3) mice at 12 wk after engraftment.
BM, bone marrow; SP, spleen. (D) Single-cell suspension from the bone marrow, spleen, and liver of hNSG or hNSG-SGM3 mice at 12–14 wk after engraftment
were analyzed by FACS. FACS plots illustrated the gating strategies for hCD33+ cells. (E) hCD33+ cells from the bone marrow of three hNSG and three hSGM3
mice were gated and subjected to tSNE reduction. Indicated marker was color mapped from blue (low density) to red (high density) into the tSNE map. (F) Bar
plot of myeloid markers in hCD33+ cells from the spleen, liver, and bone marrow of hNSG and hNSG-SGM3 mice. n = 3 mice with two-way ANOVA test. The
error bar is the SD. ****, P < 0.0001; ***, P < 0.001; and *, P < 0.05. 7-AAD, 7-amino-actinomycin D; FSC-A, forward scatter-A; FSC-H, forward scatter-H;
mCD45, mouse CD45; SSC-A, side scatter-A.
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Figure S2. hNSG-SGM3 mice promote melanoma growth in distant organs via hCD33+ cells. (A)Macroscopic tumor in the liver of hNSG or hNSG-SGM3
reconstituted with different human fetal liver CD34+ HPC donors and implanted s.c. with 107 or 106 Me275 cells for 7–8 wk. n = 2–13 mice with two-tailed
Mann-Whitney test. (B) Tumor growth and macroscopic tumor in the spleen and liver of hNSG-SGM3 reconstituted with either human fetal liver (FL) or cord
blood (CB) HPCs and implanted s.c. with 106 Me275 cells for 7–8 wk. n = 8–24 mice with two-tailed Mann-Whitney test. (C) Tumor growth and macroscopic
tumor in the spleen and liver of hNSG-SGM3mice reconstituted with human fetal liver HPCs and implanted s.c. with different number of Me275 cells. n = 8–24
mice. The error bar is the SD. (D) Localization of MART-1/gp100 (green) and DAPI (blue) in the spleen or liver of hNSG or hNSG-SGM3 at 8 wk after 107 Me275
s.c. implantation. Scale bar = 1,000 µm for the whole section and 20 µm for the selected zoom-ins. (E) Primary tumor growth curves comparing NSG-SGM3
and hNSG-SGM3 mice implanted with 107 Me275 cells s.c. n = 12–13 mice. (F) IPA analysis on myeloid genes from RNA-seq data in 14 metastatic patient
melanoma tumors for the upstream regulator. Top five regulators, STAT3, RELA, STAT1, NFKB1, and NR3C1, are illustrated with the top 20 genes of each
network, with the color intensity representing the magnitude of the expression. (G) Primary tumor growth curve in NSG-SGM3 mice after i.v. ACT of 107
hCD33+ or hCD33neg cells and subsequently implanted with 107 Me275 cells s.c. n = 7–9 mice. (H)Macroscopic Me275 tumors in the livers of NSG-SGM3 mice
after i.v. ACT of 107 hCD11b+ or hCD11bneg cells and subsequent s.c. implantation of 107 Me275 cells. n = 3 or 4 mice per recipient group. (I) FACS plots
illustrated the expression of hCD33 and CD66b on cells enriched for CD66b from naive hNSG-SGM3 mice for ACT experiment. (J) Macroscopic Me275
melanoma tumors in the livers of NSG-SGM3mice after i.v. ACT of 107 hCD45+, hCD66b+, or hCD66bneg cells. n = 4–8 mice with one-way ANOVA test. (K) FACS
plots illustrated the expression of hCD33 and CD14 on cells enriched for CD14 from naive hNSG-SGM3 mice for ACT experiment. (L) Macroscopic Me275
melanoma tumors in the livers of NSG-SGM3 mice after i.v. ACT of 107 hCD45+, hCD14+, or hCD14neg cells. n = 2–5 mice with one-way ANOVA test. (M) hNSG,
hNSG-SGM3, and hNSG-mSCF (labeled hmSCF) mice were implanted with 106 Me275 cells s.c. Primary tumor growth curves from two independent ex-
periments using two CD34+ HPC donors. n = 6–8 mice. (N) FACS plots illustrated the expression of hCD33 and FCER1A on cells enriched for FCER1A from naive
hNSG-SGM3 mice for ACT experiment. (O) Macroscopic Me275 melanoma tumor in the livers of NSG-SGM3 mice after i.v. ACT of 107 hCD45+ or hFCER1Aneg
cells. n = 4–8 mice with one-way ANOVA test. (P)Macroscopic Me275 tumors in the livers of NSG-SGM3 mice after ACT of 107 hCD117+ or hCD117neg cells i.v.
and subsequent s.c. implantation of 107 Me275 cells. n = 2–4 mice per recipient group. Mets, metastases. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01.
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Figure S3. The expression of CD117 in hNSG-SGM3 mice and metastatic melanoma tumors. (A) hCD33+ cells from the spleen and liver of hNSG-SGM3
mice were subjected to scRNA-seq and tSNE reduction. Tissue localization from two independent experiments were color mapped into the tSNE map.
(B) Violin plots showing the scRNA-seq expression value [log2 (FPKM +1)] of CD33 marker genes. (C) Expression of marker gene order by the clusters.
(D) Immunofluorescence staining of human MART-1/gp100 melanoma cells (green), CD117 (upper panels, red) or Tryptase (lower panels, red), and DAPI (blue)
in the spleen of hNSG-SGM3 mice at 8 wk after 107 Me275 s.c. implantation. Scale bar = 1 mm for the whole section (left panels) and 100 µm for the selected
zoom-ins (right panels). (E) Immunofluorescence staining in the liver of hNSG-SGM3 mice as in D. (F) Immunofluorescence staining of human MART-1/gp100
melanoma cells (white), CD11b (green), CD117 (upper panels, red), or Tryptase (lower panels, red), and DAPI (blue) in human melanoma tumors. Scale bar =
40 µm for the whole section (left panels) and 15 µm for the selected zoom-ins (right panels).
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Provided online are 10 tables. Table S1 lists the melanoma patient tumors used in the study. Table S2, an Excel table, lists the genes
in the annotated immune modules. Table S3 shows the kinetics of human engraftment in the blood of hNSG and hNSG-SGM3 mice.
Table S4 shows human engraftment in the tissues of hNSG and hNSG-SGM3 mice. Table S5, an Excel table, shows DEGs of bulk
RNA-seq on hCD33+ cells enriched from the spleen and liver of hNSG and hNSG-SGM3 mice. Table S6 shows the IPA on upstream
regulators for the myeloid genes expressed in CD33+ cells from hNSG-SGM3 mice. Table S7 shows the IPA on upstream regulators
for the myeloid genes expressed in humanmelanoma tumors. Table S8, an Excel table, shows marker genes specific for each cluster
in scRNA-seq of hCD33+ cells from hNSG-SGM3mice. Table S9, an Excel table, shows KIT signature genes identified from scRNA-seq
of hCD33+ cells from hNSG-SGM3 mice. Table S10 lists the antibodies used in the study.
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